Is DCB a new valid option for coronary revascularisation?
<p class="moderator speaker-name">Anchorperson: <span classs="personname">Robert Byrne</span></p><p class="moderator speaker-name">Spokesperson: <span classs="personname">Ran Kornowski</span></p><p class="moderator speaker-name">Discussants: <span classs="personname">Michael Joner, Bruno Scheller, Giulio Stefanini, Ron Waksman</span></p>
<div class="intervention"><div class="interventionTitle">Paclitaxel vs sirolimus-coated balloons for CAD: 2-year follow-up of two large registries</div><p class="speaker-intervention-name-img">Bernardo Cortese</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Clinical outcomes of bailout stenting after Drug-Coated Balloon angioplasty</div><p class="speaker-intervention-name-img">Mauro Gitto</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">DEB vs DES for the treatment of large native coronary artery disease: an updated meta-analysis</div><p class="speaker-intervention-name-img">Jose A. Sorolla Romero</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Head-to-head comparison of Limus vs Paclitaxel DCBs in the Treatment of In-Stent Restenosis</div><p class="speaker-intervention-name-img">Marios Sagris</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Optimal Treatment for Coronary Drug-eluting Stent In-stent Restenosis</div><p class="speaker-intervention-name-img">Peter Kulyassa</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div>